1. ARIRANG NEWS [LIVE]: Pfizer reports mild side effects from its COVID-19 vaccine  ARIRANG NEWS
  2. Bill Gates doesn't expect a virus vaccine before year-end — but he says one drugmaker has the best chance  CNBC
  3. BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls  FiercePharma
  4. Pfizer Highlights Dozens of Drugs in Its Pipeline. Here’s What It Means for the Stock.  Barron's
  5. Coronavirus Vaccine: NYU's Dr. Robyn Gershon talks COVID-19 vaccine concerns  Yahoo Finance
  6. View Full coverage on Google News

Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time consuming and costly process. In order to get both over the finish line, the German government is making a big down payment in both candidates' development.Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time consuming and costly process. In order to get both over the finish line, the German government is making a big down payment in both candidates' development.

BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls | FiercePharma

On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.

Pfizer Highlights Dozens of Drugs in Its Pipeline. Here’s What It Means for the Stock. | Barron's

Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.

Germany grants BioNTech, CureVac $745 million to speed up COVID-19 vaccine work | Reuters

Pfizer expects to have data next month on how well its COVID-19 candidate vaccine is protecting people against the coronavirus.Pfizer expects to have data next month on how well its COVID-19 candidate vaccine is protecting people against the coronavirus.

COVID-19 vaccine: Pfizer offers a positive update on its candidate

Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.

Pfizer CEO says they could know if coronavirus vaccine works by the end of October | Daily Mail Online

Bloomberg - Are you a robot?

Approval of a vaccine, however, will depend on federal regulators, Albert Bourla said.

Pfizer CEO says company will know if vaccine works by end of October

Germany boosts own vaccine makers in race for COVID-19 jabGermany boosts own vaccine makers in race for COVID-19 jab

Germany boosts own vaccine makers in race for COVID-19 jab | Taiwan News

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development | The Motley Fool

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

Pfizer Phase 3 Coronavirus Vaccine Data Slated For October

The world needs a vaccine against COVID-19, and with some 200 vaccine candidates in various stages of development, and more than 30 of these vaccines already in Phase 3 clinical trials, odds are we will get a vaccine -- probably several -- sooner than you might expect. J.P. Morgan analyst Cory KasimovThe world needs a vaccine against COVID-19, and with some 200 vaccine candidates in various stages of development, and more than 30 of these vaccines already in Phase 3 clinical trials, odds are we will get a vaccine -- probably several -- sooner than you might expect. J.P. Morgan analyst Cory Kasimov

Moderna or BioNTech: J.P. Morgan Lays Odds On the Race to a COVID-19 Vaccine

BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...

BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine - MarketWatch

404 Not Found

Germany aims to reach herd immunity through a voluntary coronavirus vaccine expected to be widely available by mid-2021, the health minister said Tuesday.Germany aims to reach herd immunity through a voluntary coronavirus vaccine expected to be widely available by mid-2021, the health minister said Tuesday.

Germany eyes voluntary COVID-19 vaccine by mid-2021 | CTV News

The estimate is in line with a recent assessment from the World Health Organization.Minister Anja Karliczek said the German govt was offering around $890 mn in funding to help three domestic firms with their vaccine research and developmentThe estimate is in line with a recent assessment from the World Health Organization.Minister Anja Karliczek said the German govt was offering around $890 mn in funding to help three domestic firms with their vaccine research and development

'No risky shortcuts': Germany eyes Covid-19 vaccine by mid-2021

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by OctoberAlbert Bourla, the head of pharmaceutical giant Pfizer, which is among the companies developing a coronavirus vaccine, said that there is a 'good chance' the company will know whether its vaccine works by the end of October.

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by October | World News – India TV

Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.

Pfizer could have a vaccine ready by end of the year, says CEO Albert Bourla

We aren’t just Public Radio, we are The Public’s Radio. Hear us on WNPN 89.3FM across Rhode Island and the Southcoast of Massachusetts.

RIPR : The Public's Radio : RIPR

Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.

Pfizer CEO expects vaccine trial results before November | WOODTV.com

Pfizer Inc.’s $48 billion gain in market value since late March, egged on by optimism for a successful Covid-19 vaccine, may soon hit a wall.

Pfizer poised for drop after US$48B climb on COVID vaccine - BNN Bloomberg

The German government says a vaccine for coronavirus would not be available globally before the middle of 2021. Research Minister Anja Karliczek said thisThe German government says a vaccine for coronavirus would not be available globally before the middle of 2021. Research Minister Anja Karliczek said this

Germany hints when COVID-19 vaccine will be available globally - Daily Post Nigeria

The German government announced Tuesday it would provide up to 750 million euros ($892 million) to support three domestic pharmaceutical companies developing vaccines for COVID-19.The German government announced Tuesday it would provide up to 750 million euros ($892 million) to support three domestic pharmaceutical companies developing vaccines for COVID-19.

Berlin pumping hundreds of millions of euros into German COVID-19 vaccine developers | TheHill

The German government announced Tuesday it would provide up to 750 million euros ($892 million) to support three domestic pharmaceutical companies developing vaccines for COVID-19.The German government announced Tuesday it would provide up to 750 million euros ($892 million) to support three domestic pharmaceutical companies developing vaccines for COVID-19.

Berlin pumping hundreds of millions of euros into German COVID-19 vaccine developers | TheHill

BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...

BioNTech wins US$445 million German grant for COVID-19 vaccine - CNA

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration ...Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-...

Pfizer, Inc. (NYSE:PFE), Astrazeneca PLC (NYSE:AZN) - Pfizer Seeks FDA Nod To Expand Late-Stage COVID-19 Vaccine Trial | Benzinga

Pfizer's RNA-based Covid-19 vaccine candidate BNT162b2 which is being developed in partnership with BioNTech is set to enter Phase 3 human trials.

Coronavirus USA: When could Pfizer's vaccine start shipping? - AS.com

In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October. In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.

Pfizer, BioNTech Say COVID-19 Vaccine Might Be Ready by End of October | BioSpace

Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.

Germany will not take risky shortcuts when developing a vaccine against COVID-19, Research Minister Anja Karliczek said on Tuesday.Germany will not take risky shortcuts when developing a vaccine against COVID-19, Research Minister Anja Karliczek said on Tuesday.

Germany won't take risky short-cuts on COVID-19 vaccines—minister | Inquirer News

GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.

Pfizer aims to learn if its COVID-19 vaccine works by the end of October | News | wfsb.com

NEW YORK (REUTERS) - Pfizer Inc said on Monday (Sept 14) that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is developing with German partner BioNTech.. Read more at straitstimes.com.United States News -NEW YORK (REUTERS) - Pfizer Inc said on Monday (Sept 14) that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is

Pfizer says enrolled more than 29,000 people in its Covid-19 vaccine trial, United States News & Top Stories - The Straits Times

Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.

Pfizer COVID-19 vaccine may be ready for approval by October, CEO says

Here are all the latest updates on COVID-19 vaccine candidates.Here are all the latest updates on COVID-19 vaccine candidates.

Coronavirus vaccine update September 14 | Check out all COVID-19 vaccine updates from around the world

Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.

Pfizer could have working Covid-19 vaccine before the end of 2020 | Buzz.ie

Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.

Pfizer stock rockets as potential COVID-19 vaccine delivery by end of 2020

Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.

Pfizer should know if COVID vaccine works by end of October

CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.

Pfizer CEO: We'll Know if Vaccine Works By End of October

Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.

COVID-19 vaccine manufacturing has begun at a risk, will be ready by year-end: Pfizer CEO - Republic World

Access Denied

Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.

Americans could get Covid vaccine before the end of this year, Pfizer CEO says

Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.

Americans could get Covid vaccine before the end of this year, Pfizer CEO says

Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.

Coronavirus: Pfizer vaccine could be distributed by year’s end, CEO says